

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

REC'D	18 FEB 2005
WIPO	PCT

Intyg
Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0400208-5
Patent application number

(86) Ingivningsdatum 2004-02-02
Date of filing

Stockholm, 2004-11-25

För Patent- och registreringsverket
For the Patent- and Registration Office

Hjördis Segerlund

Hjördis Segerlund

Avgift
Fee 170:-

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

CHEMICAL COMPOUNDS

The present invention concerns piperidine derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.

Pharmaceutically active N-(2-hydroxyprop-1-yl)piperidine derivatives are disclosed in WO 03/068743.

Histamine is a basic amine, 2-(4-imidazolyl)-ethylamine, and is formed from histidine by histidine decarboxylase. It is found in most tissues of the body, but is present in high concentrations in the lung, skin and in the gastrointestinal tract. At the cellular level inflammatory cells such as mast cells and basophils store large amounts of histamine. It is recognised that the degranulation of mast cells and basophils and the subsequent release of histamine is a fundamental mechanism responsible for the clinical manifestation of an allergic process. Histamine produces its actions by an effect on specific histamine G-protein coupled receptors, which are of three main types, H1, H2 and H3. Histamine H1 antagonists comprise the largest class of medications used in the treatment of patients with allergic disorders, for example rhinitis and urticaria. Antagonists of H1 are useful in controlling the allergic response by for example blocking the action of histamine on post-capillary venule smooth muscle, resulting in decreased vascular permeability, exudation and oedema. The antagonists also produce blockade of the actions of histamine on the H1 receptors on c-type nociceptive nerve fibres, resulting in decreased itching and sneezing.

Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a role in the maturation of cells of the immune system.

Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or α) and Cys-Cys (C-C, or β) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).


The C-C chemokines include potent chemoattractants of monocytes and lymphocytes, but not neutrophils, such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxins and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β).

Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated 10 CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

Viral infections are known to cause lung inflammation. It has been shown 15 experimentally that the common cold increases mucosal output of eotaxin in the airways. Instillation of eotaxin into the nose can mimic some of the signs and symptoms of a common cold. (See, Greiff L *et al* Allergy (1999) 54(11) 1204-8 [Experimental common cold increase mucosal output of eotaxin in atopic individuals] and Kawaguchi M *et al* Int. Arch. Allergy Immunol. (2000) 122 S1 44 [Expression of eotaxin by normal airway 20 epithelial cells after virus A infection].)

The compounds of the present invention are useful in the treatment of CCR3 mediated disease states (such as asthma and/or rhinitis) and show good specificity (for example 100-fold difference in activity) for the CCR3 receptor over other receptors present in a mammal such as G-Protein Coupled Receptors (for example: alpha 1 adrenoceptor and 25 5HT_{2B} receptors) and ion channels (for example: the human ether-a-go-go-related gene (hERG) potassium channel).

The present invention provides a compound of formula (I):



wherein:

30 R¹ is phenyl optionally substituted by halogen, cyano, C₁₋₄ alkyl or C₁₋₄ haloalkyl; R² is hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl; and,

R^3 is a group having an NH or OH that has a calculated or measured pKa of 1.0 to 8.0; or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present invention covers all such isomers and mixtures thereof in all proportions.

Suitable salts include acid addition salts such as a hydrochloride, dihydrochloride, hydrobromide, phosphate, sulfate, acetate, diacetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulfonate or *p*-toluenesulfonate. Salts also include metal salts, such as an alkali metal salt (for example a sodium or potassium salt) or an alkaline earth metal salt (for example magnesium or calcium).

The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.

The pKa of a compound of formula (I) is calculated using ACD/Labs 6.00 software available from Advanced Chemistry Development Inc, 90 Adelaide Street, West Toronto, Ontario, Canada. The pKa of a compound of formula (I) is measured using one of the methodologies recited below.

Halogen is, for example fluorine or chlorine.

Alkyl groups and moieties are straight or branched chain and are, for example, methyl, ethyl, *n*-propyl, *iso*-propyl or *tert*-butyl.

Cycloalkyl is monocyclic and is, for example, cyclopropyl, cyclopentyl or cyclohexyl.

Haloalkyl is an alkyl group carrying one or more (such as 1 to 6) halogen (such as chloro or fluoro atoms) and is, for example, CF_3 , CH_2CF_3 or C_2F_5 .

Fluoroalkyl is an alkyl group carrying one or more (such as 1 to 6) fluoro atoms and is, for example, CH_2F , CF_3 , CH_2CF_3 or C_2F_5 .

In one aspect the present invention provides a compound of formula (I) wherein R^1 is phenyl optionally substituted by halogen, cyano or C_{1-4} alkyl.

In another aspect the present invention provides a compound of formula (I) wherein R^1 is phenyl substituted with one, two or three of: halogen (such as fluoro or chloro), cyano or C_{1-4} alkyl (such as methyl); for example R^1 is phenyl substituted by one, two or three of: fluoro, chloro, methyl or cyano. In another aspect R^1 is phenyl substituted by one, two or three (such as two or three) of: fluoro, chloro, cyano or methyl (such as chloro, cyano or methyl). R^1 is, for example, 2-methyl-4-chlorophenyl, 3-methyl-2,4-dichlorophenyl, 2-

methyl-3,4-dichlorophenyl, 3-chloro-4-cyanophenyl, 3,4-difluorophenyl, 3-fluoro-4-chlorophenyl or 4-chlorophenyl. In a still further aspect R¹ is 3,4-dichlorophenyl or 3-chloro-4-cyanophenyl.

In a further aspect of the invention R¹ is phenyl substituted by one or more of 5 chloro or methyl and optionally further substituted by fluoro. For example R¹ is 2-methyl-4-chlorophenyl, 3-methyl-2,4-dichlorophenyl, 2-methyl-3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 4-chlorophenyl or 3,4-dichlorophenyl.

In a still further aspect the present invention provides a compound of formula (I) 10 wherein R² is hydrogen or C₁₋₄ alkyl (such as methyl).

The acidic NH of R³ can be part of a ring or it can be part of a substituent on an 15 aryl or heterocyclyl ring. The acidic OH of R³ can be a substituent or part of a substituent (such an OH in a carboxylic acid group) on an aryl or heterocyclyl ring. Thus, for example, the acidic OH of R³ can be part of an acidic phenol, in a carboxylic acid or in a hydroxy aromatic heterocyclyl (such as a hydroxypyridine which may tautomerise to a pyridone).

Aryl includes optionally substituted phenyl and naphthyl.

Heterocyclyl is an optionally substituted aromatic or non-aromatic 5- or 6-membered ring, comprising, as required, at least one heteroatom selected from the group comprising nitrogen, oxygen and sulphur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Heterocyclyl is, for example, furyl, thienyl (also known as thiophenyl), 20 pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl (for example in 2-oxo-2,3-dihydro-1,3-thiazolyl), isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl (for example in 1H-1,2,3-triazolyl), pyridinyl (for example in 6-oxo-1,6-dihydro-pyridinyl) or pyrimidinyl.

In an aspect of the present invention the acidic NH of R³ is part of a ring (for 25 example part of a pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, pyridinyl or pyrimidinyl ring) or part of a substituent on an aryl (for example phenyl or naphthyl) or heterocyclyl (for example furyl, thienyl, pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, pyridinyl or pyrimidinyl) ring.

In another aspect of the present invention the acidic OH of R³ is a substituent or 30 part of a substituent (such an OH in a carboxylic acid group) on an aryl (for example phenyl or naphthyl) or heterocyclyl (for example furyl, thienyl, pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, isothiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl,

triazolyl, pyridinyl or pyrimidinyl) ring. Thus, for example, the acidic OH of R³ can be part of an acidic phenol, in a carboxylic acid or in a hydroxy aromatic heterocycl (such as a hydroxypyridine which may tautomerise to a pyridone).

In one aspect of the present invention when the acidic NH of R³ is part of a ring it 5 is, for example, part of a 2-oxo-thiazol-5-yl, 2-oxo-oxazol-5-yl, 2-oxo-imidazol-5-yl, 1H-1,2,3-triazol-4-yl, 4-oxo-1H-1,4-dihydropyridin-3-yl, 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl, 6-oxo-1H-1,6-dihydropyridin-3-yl or 2H-tetrazol-5-yl ring.

In a further aspect of the present invention when the acidic NH of R³ is part of a substituent it is, for example, part of NHS(O)₂(C₁₋₄ alkyl).

10 In another aspect the present invention provides a compound of formula (I) wherein R³ is a group having an NH or OH that has a calculated or measured pKa of 3 to 6.5.

In yet another aspect the present invention provides a compound of formula (I) wherein R³ is a group having an NH or OH that has a calculated or measured pKa of 1.0 to 8.0 (for example 3 to 6.5), the group R³ being, for example,

15 • 2-oxo-thiazol-5-yl having a suitable electron withdrawing substituent {such as C₁₋₄ fluoroalkyl (for example CF₃, CH₂CF₃ or C₂F₅), an aryl group (for example 4-fluorophenyl), a heterocycl group (for example pyridyl) or a group CH₂S(O)₂(C₁₋₄ alkyl)} in the 4-position;

20 • 2-oxo-oxazol-5-yl having a suitable electron withdrawing substituent {such as C₁₋₄ fluoroalkyl (for example CF₃, CH₂CF₃ or C₂F₅) or CH₂S(O)₂(C₁₋₄ alkyl)} in the 4-position;

25 • 1H-1,2,3-triazol-4-yl having a suitable substituent {such as C₁₋₄ alkyl (for example CH₃), C₃₋₆ cycloalkyl (for example cyclopropyl), C₁₋₄ fluoroalkyl (for example CF₃, CH₂CF₃ or C₂F₅), S-R⁴ (wherein R⁴ is C₁₋₄ alkyl [for example CH₃], C₁₋₄ fluoroalkyl [for example CF₃, CH₂CF₃ or C₂F₅] or C₃₋₆ cycloalkyl [for example cyclopropyl]), NHS(O)₂(C₁₋₄ alkyl), an aryl group (for example 4-fluorophenyl), a heterocycl group (for example pyridyl) or a group CH₂S(O)₂(C₁₋₄ alkyl)} in the 5-position;

30 • 4-oxo-1H-1,4-dihydropyridin-3-yl having a suitable electron withdrawing substituent {such as C₁₋₄ fluoroalkyl (for example CF₃ or C₂F₅)} in the 2-position;

• 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl having a suitable substituent {such as C₁₋₄ alkyl (for example CH₃), C₃₋₆ cycloalkyl (for example cyclopropyl) or C₁₋₄ fluoroalkyl (for example CF₃, CH₂CF₃ or C₂F₅)} in the 3-position;

- 6-oxo-1H-1,6-dihdropyridin-3-yl having a suitable electron withdrawing substituent {such as C₁₋₄ fluoroalkyl (for example CF₃, CH₂CF₃ or C₂F₅) or cyano} in the 2-position or the 5-position and optionally substituted in other positions;
- 2H-tetrazol-5-yl;
- a CO₂H group on an optionally substituted phenyl or naphthyl ring; or,
- an NHS(O)₂(C₁₋₄ alkyl) (for example NHS(O)₂CH₃) group on an optionally substituted aromatic heterocyclyl ring (for example pyridinyl, pyrimidinyl or thiazolyl);

5 or, where possible, a tautomer thereof.

10 Where indicated above that a heterocyclyl ring may be optionally substituted it can be optionally substituted by, for example: fluoro, chloro, bromo, C₁₋₄ alkyl (for example methyl), C₃₋₆ cycloalkyl (for example cyclopropyl), C₁₋₄ fluoroalkyl (for example CF₃, CH₂CF₃ or C₂F₅), S-R⁴ (wherein R⁴ is C₁₋₄ alkyl [for example CH₃], C₁₋₄ fluoroalkyl [for example CF₃, CH₂CF₃ or C₂F₅] or C₃₋₆ cycloalkyl [for example cyclopropyl]), cyano,

15 S(O)₂(C₁₋₄ alkyl) (for example S(O)₂CH₃) or S(O)₂NH(C₁₋₄ alkyl) (for example S(O)₂NHCH₃).

Where indicated above that a phenyl or naphthyl ring in R³ may be optionally substituted it can be optionally substituted by, for example, halogen, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ fluoroalkyl (for example CF₃, CH₂CF₃ or C₂F₅)}, OCF₃, SCF₃, nitro, S(C₁₋₄ alkyl), S(O)(C₁₋₄ alkyl), S(O)₂(C₁₋₄ alkyl), S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂, NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl).


In one aspect of the invention R³ is

- 2-oxo-thiazol-5-yl having C₁₋₄ fluoroalkyl (for example CF₃, CH₂CF₃ or C₂F₅) in the 4-position;
- 1H-1,2,3-triazol-4-yl having a suitable substituent {such as C₁₋₄ alkyl (for example CH₃) or S-R⁴ (wherein R⁴ is C₁₋₄ fluoroalkyl [for example CF₃, CH₂CF₃ or C₂F₅])} in the 5-position;
- 2,6-dioxo-1H-1,2,3,6-tetrahydropyrimidin-4-yl having a suitable substituent {such as C₁₋₄ alkyl (for example CH₃) or C₁₋₄ fluoroalkyl (for example CF₃, CH₂CF₃ or C₂F₅)} in the 3-position;
- 6-oxo-1H-1,6-dihdropyridin-3-yl having a suitable electron withdrawing substituent {such as C₁₋₄ fluoroalkyl (for example CF₃, CH₂CF₃ or C₂F₅) or cyano} in the 2-position or the 5-position and optionally substituted in other positions;

- a CO_2H group on an optionally substituted naphthyl ring; or,
- an $\text{NHS(O)}_2(\text{C}_{1-4} \text{ alkyl})$ (for example $\text{NHS(O)}_2\text{CH}_3$) group on an optionally substituted aromatic heterocycl ring (for example pyridinyl, pyrimidinyl or thiazolyl);

5 or, where possible, a tautomer thereof; the optional substituents being as defined above.


In yet another aspect the present invention provides a compound of formula (I) wherein the 2-hydroxy group has the stereochemistry shown below:



10 Compounds of the invention are illustrated in the Examples below.

Compounds of the present invention can be prepared by methods described, or analogous to those described, in the art (for example WO 03/068743). Intermediates for such processes can be prepared by methods described, or analogous to those described, in the art (for example WO 03/068743).

15 A compound of formula (I) can be prepared by reacting a compound of formula (II):




wherein R^1 and R^2 are as defined above, with a compound of formula (III):




20 wherein L^1 is a leaving group (for example a hydroxyl or chloride leaving group) in the presence of a base (for example diisopropylethylamine), optionally in the presence of a coupling agent (for example bromo-tris-pyrrolidinophosphonium hexafluorophosphate, PyBrOP or O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate).

25 A compound of formula (II) can be prepared as described in WO 00/58305 or WO 01/77101, or by reacting a compound of formula (IV):




wherein R^1 is defined above, with:

(i) a compound of formula (V):



5 in which L^2 is a leaving group (for example chloro or nosyloxy {3-NO₂-C₆H₄-S(O)₂O-}) followed by reaction with ammonia, an amine R^2 -NH₂ or with sodium azide and subsequent reduction with, for example, triphenylphosphine; or,

(ii) with a compound of formula (VI):



10 in which P^1 and P^2 are, alone or together, suitable protective groups (for example together they form phthalamide), or either P^1 or P^2 is R^2 , followed by deprotection using, for example when P^1 and P^2 form phthalamide, hydrazine.

A compound of formula (V) can be obtained commercially or can be prepared using methods described in the literature.

15 A compound of formula (VI) can be prepared by reacting (R) or (S) glycidol under Mitsunobu reaction conditions with, for example, phthalimide, 1,1-(azodicarbonyl) dipiperidine and tributylphosphine (Tetrahedron Lett. 1993, 34, 1639).

Further, a compound of formula (I) can be prepared by routine adaptation of: the routes described above, methods described in the art, or the Examples recited below. The
 20 intermediates identified above are commercially available or can be prepared by using or adapting methods described in the art.

In another aspect the present invention provides processes for the preparation of compounds of formula (I).

The compounds of the invention have activity as pharmaceuticals, in particular as
 25 modulators of chemokine receptor (for example CCR3) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or

immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).

In one aspect examples of these conditions are:

- (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
- (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
- (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
- (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
- (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
- (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome,

leprosy (such as lepromatous leprosy), Peridental disease, Sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle.

The compounds of the invention are also H1 antagonists and may be used in the treatment of allergic disorders.

5 The compounds of the invention may also be used to control a sign and/or symptom of what is commonly referred to as a cold (for example a sign and/or symptom of a common cold or influenza or other associated respiratory virus infection).

10 According to a further feature of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).

15 According to a further feature of the present invention there is provided a method for modulating chemokine receptor activity (for example CCR3 receptor activity), or antagonising H1, in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof.

The invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament.

20 In another aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (for example CCR3 receptor activity), or antagonising H1, in a warm blooded animal, such as man).

25 The invention further provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:

(1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or

pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;

5 (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behçet's disease, Sjogren's syndrome or systemic sclerosis;

10 (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;

15 (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);

20 (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or

25 (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle;

30 in a warm blooded animal, such as man.

In a further aspect a compound of formula (I), or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; or rhinitis {including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or

pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis}.

In a still further aspect a compound of formula (I), or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma.

5 The present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of asthma or rhinitis.

10 The present invention further provides a method of treating a chemokine mediated disease state (for example a CCR3 mediated disease state, such as asthma) in a warm blooded animal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof.

15 In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR3 receptor) activity or antagonising H1, said ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

20 Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier. In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will, for example, comprise from 0.05 to 25 99%w (per cent by weight), such as from 0.05 to 80%w, for example from 0.10 to 70%w, such as from 0.10 to 50%w, of active ingredient, all percentages by weight being based on total composition.

30 The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions,

dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 5 0.1mg and 1g of active ingredient.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.

Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 0.01mgkg^{-1} to 100mgkg^{-1} of the compound, for example in the range 10 of 0.1mgkg^{-1} to 20mgkg^{-1} of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being 15 administered 1 to 4 times per day.

The invention further relates to combination therapies or compositions wherein a compound of formula (I), or a pharmaceutically acceptable salt, solvate or a solvate of a salt thereof, or a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate or a solvate of a salt thereof, is administered 20 concurrently (possibly in the same composition) or sequentially with an agent for the treatment of any one of the above disease states.

In particular, for the treatment of the inflammatory diseases rheumatoid arthritis, psoriasis, inflammatory bowel disease, COPD, asthma and allergic rhinitis a compound of the invention can be combined with a TNF- α inhibitor (such as an anti-TNF monoclonal 25 antibody (such as Remicade, CDP-870 and D.sub2.E.sub7.), or a TNF receptor immunoglobulin molecule (such as Enbrel.reg.)), a non-selective COX-1 / COX-2 inhibitor (such as piroxicam or diclofenac; a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen; a fenamate such as mefenamic acid, indomethacin, sulindac or apazone; a pyrazolone such as phenylbutazone; or a salicylate such as aspirin), 30 a COX-2 inhibitor (such as meloxicam, celecoxib, rofecoxib, valdecoxib or etoricoxib) low dose methotrexate, lefunomide; ciclesonide; hydroxychloroquine, d-penicillamine or auranofin, or parenteral or oral gold.

The present invention still further relates to the combination of a compound of the invention together with:

- a leukotriene biosynthesis inhibitor, a 5-lipoxygenase (5-LO) inhibitor or a 5-lipoxygenase activating protein (FLAP) antagonist, such as zileuton, ABT-761, 5 fenleuton, tepoxalin, Abbott-79175, Abbott-85761, an N-(5-substituted)-thiophene-2-alkylsulfonamide, a 2,6-di-tert-butylphenol hydrazones, a methoxytetrahydropyran such as Zeneca ZD-2138, SB-210661, a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinoline compound such as L-746,530; an indole or quinoline compound such as MK-591, 10 MK-886 or BAY x 1005;
- a receptor antagonist for a leukotriene LTB₄, LTC₄, LTD₄ or LTE₄ selected from the group consisting of a phenothiazin-3-one such as L-651,392; an amidino compound such as CGS-25019c; a benzoxalamine such as ontazolast; a benzenecarboximidamide such as BII 284/260; or a compound such as 15 zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A) or BAY x 7195;
- a PDE4 inhibitor including an inhibitor of the isoform PDE4D;
- an antihistaminic H₁ receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine or chlorpheniramine;
- 20 • a gastroprotective H₂ receptor antagonist;
- an α₁- and α₂-adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride or 25 ethylnorepinephrine hydrochloride;
- an anticholinergic agent such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine;
- a β₁- to β₄-adrenoceptor agonist such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, 30 orciprenaline, bitolterol mesylate or pirbuterol, or a methylxanthanine including theophylline and aminophylline; sodium cromoglycate; or a muscarinic receptor (M₁, M₂, and M₃) antagonist;
- an insulin-like growth factor type I (IGF-1) mimetic;

- an inhaled glucocorticoid with reduced systemic side effects, such as prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate or mometasone furoate;
- an inhibitor of a matrix metalloprotease (MMP), such as a stromelysin, a collagenase, or a gelatinase or aggrecanase; such as collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) or MMP-12;
- a modulator of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family;
- an osteoporosis agent such as roloxifene, droloxifene, lasofoxifene or fosomax;
- an immunosuppressant agent such as FK-506, rapamycin, cyclosporine, azathioprine or methotrexate;
- a compound useful in the treatment of AIDS and/or HIV infection for example: an agent which prevents or inhibits the viral protein gp120 from engaging host cell CD4 {such as soluble CD4 (recombinant); an anti-CD4 antibody (or modified / recombinant antibody) for example PRO542; an anti-group120 antibody (or modified / recombinant antibody); or another agent which interferes with the binding of group120 to CD4 for example BMS806}; an agent which prevents binding to a chemokine receptor, other than CCR5, used by the HIV virus {such as a CXCR4 agonist or antagonist or an anti-CXCR4 antibody}; a compound which interferes in the fusion between the HIV viral envelope and a cell membrane {such as an anti-group 41 antibody; enfuvirtide (T-20) or T-1249}; an inhibitor of DC-SIGN (also known as CD209) {such as an anti-DC-SIGN antibody or an inhibitor of DC-SIGN binding}; a nucleoside/nucleotide analogue reverse transcriptase inhibitor {for example zidovudine (AZT), nevirapine, didanosine (ddI), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir, adefovir or tenofovir (for example as free base or as disoproxil fumarate)}; a non-nucleoside reverse transcriptase inhibitor {for example nevirapine, delavirdine or efavirenz}; a protease inhibitor {for example ritonavir, indinavir, saquinavir (for example as free base or as mesylate salt), nelfinavir (for example as free base or as mesylate salt), amprenavir, lopinavir or atazanavir (for example as free base or as sulphate salt)}; a

ribonucleotide reductase inhibitor {for example hydroxyurea}; or an antiretroviral {for example emtricitabine}; or,

- an existing therapeutic agent for the treatment of osteoarthritis, for example a non-steroidal anti-inflammatory agent (hereinafter NSAID's) such as piroxicam or 5 diclofenac, a propionic acid such as naproxen, flubiprofen, fenoprofen, ketoprofen or ibuprofen, a fenamate such as mefenamic acid, indomethacin, sulindac or apazone, a pyrazolone such as phenylbutazone, a salicylate such as aspirin, a COX-2 inhibitor such as celecoxib, valdecoxib, rofecoxib or etoricoxib, an analgesic or intra-articular therapy such as a corticosteroid or a hyaluronic acid such as hyalgan 10 or synvisc, or a P2X7 receptor antagonist.

The present invention still further relates to the combination of a compound of the invention together with: (i) a tryptase inhibitor; (ii) a platelet activating factor (PAF) antagonist; (iii) an interleukin converting enzyme (ICE) inhibitor; (iv) an IMPDH inhibitor; (v) an adhesion molecule inhibitor including a VLA-4 antagonist; (vi) a 15 cathepsin; (vii) a MAP kinase inhibitor; (viii) a glucose-6 phosphate dehydrogenase inhibitor; (ix) a kinin-B₁ and B₂-receptor antagonist; (x) an anti-gout agent, e.g., colchicine; (xi) a xanthine oxidase inhibitor, e.g., allopurinol; (xii) an uricosuric agent, e.g., probenecid, sulfinopyrazone or benzbromarone; (xiii) a growth hormone secretagogue; (xiv) a transforming growth factor (TGF β); (xv) a platelet-derived growth factor (PDGF); 20 (xvi) a fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (xvii) a granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) a capsaicin cream; (xix) a Tachykinin NK₁ and NK₃ receptor antagonist selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; (xx) an elastase inhibitor selected from the group consisting of UT-77 and ZD-0892; (xxi) a TNF α converting 25 enzyme inhibitor (TACE); (xxii) an induced nitric oxide synthase inhibitor (iNOS); or (xxiii) a chemoattractant receptor-homologous molecule expressed on TH2 cells (a CRTH2 antagonist).

30 The pKa of a compound of formula (I) is measured using one of the following methodologies.

Method A

The apparatus used consists of a Sirius GLpK_a instrument with DPAS (Dip Probe Absorption Spectroscopy) attachment. Key elements of the apparatus are a Sirius pH

electrode, stirrer, titrant dispensing tubes, a multi-tipped dispenser, motor driven dispensing syringes, fibre optic UV probe and diode array detector. In addition, solutions in PTFE containers of ionic strength adjusted (0.10M KCl) distilled water, nominally 0.50M HCl, nominally 0.50M KOH and 80% v/v methanol:water are also housed within the instrument. The titration solutions are constantly purged with oxygen free nitrogen. The reservoir for the potassium hydroxide solution is further protected from atmospheric contamination by a soda-lime guard-tube. Samples are placed in titration vessels which in turn are placed in a movable autosampler tray (maximum capacity 48 samples). The electrode, stirrer, dispensing tubing/tips and DPAS probe are housed on a movable, automated z-tower unit, which, controlled by software, positions itself in the appropriate titration vessel when titrating. The Sirius GLpK_a instrument is directly connected to a dedicated PC supporting software for assay setup and subsequent data analysis. Assays are set up using the GlpKaControl software and results are analysed using the pKaLOGP and pKaUV software on the PC. The software also allows determination of multiple pK_as using complex curve fitting analyses.

Method B: Potentiometric Method

Two types of potentiometric titrations may be performed in order to determine a compound's pK_a/pK_as; a purely aqueous titration (recommended for fairly water soluble compounds) and a cosolvent titration, where variable amounts of methanol are added to the sample in addition to ionic strength adjusted water (recommended for compounds which are not soluble in water). For the latter, a value for the compound's pK_a in pure ionic strength adjusted water can be estimated by the Yasuda-Shedlovsky procedure. This involves measuring the apparent pK_a of the compound at three known weight percentages of methanol:water (transposed into reciprocals of the dielectric constants of the medium, $1/\epsilon_r$) and then extrapolating to 0 wt% methanol ($1/\epsilon_r = 1.282 \times 10^{-3}$).

The GLpK_a instrument unit also houses two aqueous wash containers (containing distilled water), a waste beaker (to dispense extraneous solutions into) and a container holding pH 7.00 buffer solution for the electrode to be immersed in during periods between titrations. Each time a set of titrations is carried out, these solutions are replaced. Position 1 in the autosampler contains a titration vessel containing pH 7.00 buffer solution (changed for each titration set). For each titration set to be run, position 2 houses a titration vessel into which ionic strength adjusted water is dispensed (typically 15.00ml). This in turn is

adjusted to pH 1.80 with aqueous HCl and then titrated to pH 12.20 by gradual addition of aqueous KOH. This is referred to as a blank titration and is employed by the pKaLogP software in order to calibrate the pH electrode and to standardise the HCl solution, using the so-called four-plus parameter procedure. Periodically, (typically every 3 months, or 5 when the titration solutions run low) the titration solutions are replaced and the KOH solution standardised against potassium hydrogen phthalate using a standardisation procedure within the GLpKaControl software. Between 1-2 mg of each sample must be accurately weighed out. Samples are placed in provided glass titration vessels. The weight of compound must be entered into the GLpKaControl software. Other parameters that 10 need to be entered are; the molecular weight of the compound, assay type (aqueous, cosolvent), number of assays in the beaker (1 for aqueous titrations, 3 for cosolvent/mixed solvent titrations), formula (eg. X for a compound not present as a salt, or XHCl for a compound introduced as a hydrochloride salt), expected number of pK_as (from known structure), minimum pH (1.80 for operational minimum of electrode), maximum pH (12.20 for operational maximum of electrode), first assay direction (low to high pH recommended 15 for bases, high to low pH recommended for acids), starting aqueous phase volume (minimum 8.00 ml, typically 15.00 ml for purely aqueous titrations and 9.00 ml for mixed solvent titrations), and pH step between points ($\Delta\text{pH}=0.10$ units recommended). If mixed solvent titrations are carried out on a compound, then additional information needs to be 20 entered; assay direction for second and third titrations (see first assay direction), and additional water volume for second and third assays (automatically calculated when using the cosolvent weight percentage tool).

A number of samples (maximum 48) are placed in the autosampler and the pertinent information for each titration (weight of compound, molecular weight etc.) 25 downloaded to the GLpK_a instrument from the dedicated PC. The "run assays" option on the GLpK_a instrument is selected and the titration run proceeds. At the end of the run, the titration data is uploaded to the PC and analysed using the pKaLOGP software. The first sample to be analysed is the blank titration. Curve fitting procedures are used to fit the measured data to a theoretical curve allowing the derivation of the exact concentration of the HCl solution, and also the values of various parameters (four-plus parameters) which 30 characterise the behaviour of the electrode as a function of pH. These data are then used in the subsequent analysis of the other samples. The rest of the samples are analysed using further curve fitting procedures that extract the pK_as of the compound by fitting the

observed data to a theoretical curve. For cosolvent titrations the observed pKas from each sample at different percentages of methanol are analysed using the Yasuda-Shedlovsky procedure in the pKaLOGP software which extrapolates the observed pKas to the true pKas in 100% aqueous solution.

5

Method C: DPAS (Dip Probe Absorption Spectroscopy) Method

This method determines pKas by measuring UV spectra of a compound as a function of pH. This method is most suitable for compounds where the ionising centre is situated close to an aromatic or conjugated system within the molecule such that a change 10 in the extent of ionisation will lead to a change in the UV spectrum. Due to the good sensitivity of UV spectroscopy, this method is suitable for rather insoluble compounds.

This method requires a blank titration to be run in just the same way as the 15 potentiometric method. However, for the samples, two vials are required for each sample. Into one vial is placed a small amount of a DMSO solution of the compound (typically 50 μ l of a 1.5 mM solution) along with some phosphate buffer to give some pH stability during the titration (typically 100 μ l of an aqueous solution prepared from 0.2 g potassium dihydrogen orthophosphate and 100 ml 0.1 M KCl solution). The titrator will then add water (typically 10 ml) to this solution and then carry out a pH titration while collecting 20 UV spectra at each pH. The second vial should contain an equivalent volume of neat DMSO and an equivalent volume of phosphate buffer. The titrator will then add an equivalent volume of water to this solution and take a UV spectrum of it to act as a reference (this is actually done before the pH titration of the corresponding sample solution).

Again the first sample to be analysed is the blank titration which allows 25 determination of the exact HCl concentration and the values of four-plus parameters. The pKaUV software is then used to extract the pKas of the compound from the 3 dimensional data (absorbance, wavelength, pH) that was collected during the titration. The software uses a complex algorithm (target factor analysis) to extract the UV spectrum of each protonation state of the molecule as well as each pKa of the molecule from the raw 3 30 dimensional data.

The invention will now be illustrated by the following non-limiting Examples in which, unless stated otherwise:

(i) when given, ^1H NMR data is quoted and is in the form of delta values for major

diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300MHz or 400MHz using perdeuterio DMSO-D6 (CD_3SOCD_3), methanol-D4 (CD_3OD) or CDCl_3 as the solvent unless otherwise stated;

5 (ii) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected by electron impact (EI) or fast atom bombardment (FAB) or electrospray (ESI); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - $(\text{M}+\text{H})^+$;

10 (iii) the title and subtitle compounds of the examples and methods were named using the ACD/Index name program version 4.55 from Advanced Chemistry Development, Inc;

(iv) unless stated otherwise, reverse phase HPLC was conducted using a Symmetry, NovaPak or Xterra reverse phase silica column; and


(v) the following abbreviations are used:

DMF	N,N-Dimethylformamide
HPLC	High pressure liquid chromatography
RPHPLC	Reverse phase high pressure liquid chromatography
HATU	O-(7-Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
THF	Tetrahydrofuran
DCM	Dichloromethane

15

Preparation 1

(2R)-1-Amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol.



Step 1: 4-(3,4-Dichlorophenoxy)piperidine

20 4-Hydroxypiperidine (50g, 494mmol) was added portionwise to a stirred suspension of potassium *tert*-butoxide (110.9g, 990mmol) in THF (900ml) at room temperature and under nitrogen. The mixture was heated at reflux and 1,2-dichloro-4-fluorobenzene (98g, 594mmol) added dropwise over 30 minutes. The mixture was stirred at reflux for another 1 hour then cooled down to room temperature, diluted with ethyl acetate (500ml) and washed with water (500ml). The organic phase was diluted further


with ethyl acetate (500ml) and extracted with 1M hydrochloric acid (200ml). The aqueous extract was adjusted to pH>10 by addition of a solution of sodium hydroxide and extracted twice with *tert*-butylmethyl ether (750ml). The organic extracts were dried over magnesium sulfate, filtered and concentrated under vacuum to yield the sub-title compound as a dark oil which was used as such in the next step.

5

MS (ESI+ve) 246/248 (M+H)⁺

¹H NMR δ (CDCl₃) 1.60-1.70 (2H, m), 1.97-2.03 (2H, m), 2.75 (2H, td), 3.15 (2H, dt), 4.29-4.37 (1H, m), 6.78 (1H, dd), 7.00 (1H, d), 7.31 (1H, d).

10 Step 2: (2S)-1-Azido-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol



(2*R*)-Oxiran-2-ylmethyl 3-nitrobenzenesulfonate (21.1g, 81.3mmol) in DMF (300ml) was treated with triethylamine (22.6ml, 163.0mmol) followed by 4-(3,4-dichlorophenoxy)-piperidine (20g, 81.3mmol). The mixture was stirred overnight at 60°C. Sodium azide (16g, 243.9mmol) was added to the mixture and the reaction was stirred for a further 72h. The solution was carefully concentrated under vacuum and the residue was diluted with water (600ml), extracted with ethyl acetate (1500ml). The organic layer was washed twice with water (500ml), then brine (200ml) and concentrated under vacuum to afford an oil.

20

Step 3: (2*R*)-1-Amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol

The resulting oil from Step 2 was dissolved in wet tetrahydrofuran (225ml) and was treated with triphenylphosphine (53.3g, 203mmol). The reaction was heated at 60°C and stirred for 4h. The solvent was removed under vacuum, the residue re-dissolved into 2N hydrochloric acid (1L) and the aqueous layer was extracted with ethyl acetate (3 times 700ml). The aqueous phase was basified with a 2N sodium hydroxide solution and extracted with dichloromethane (3 times 1L). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under vacuum. The crude material was purified by chromatography (8% 7N ammonia in methanol/DCM) to give the title compound as a yellow oil (17g).

30


MS (APCI+ve) 319/321 (M+H)⁺

¹H NMR δ (CDCl₃) 1.90-1.72 (2H, m), 2.06-1.91 (2H, m), 2.46-2.21 (3H, m), 2.60-2.49 (1H, m), 2.65 (1H, d), 2.72-2.61 (1H, m), 2.82 (1H, d), 2.94-2.84 (1H, m), 3.74-3.62 (1H, m), 4.0 (1H, app. sept.), 6.75 (1H, dd), 7.00 (1H, d), 7.31 (1H, d).

5

Preparation 2

This shows the preparation of (2*R*)-1-amino-3-[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]propan-2-ol



10 piperidine.


MS (APCI+ve) 333/335 (M+H)⁺

¹H NMR δ (CD₃OD) 1.92-1.75 (2H, m), 2.08-1.90 (2H, m), 2.72-2.57 (1H, m), 2.93-2.72 (4H, m), 3.35-3.24 (2H, m), 3.88-3.71 (1H, m), 4.54-4.37 (1H, m), 6.94 (2H, d), 7.25 (2H, d).

15

Preparation 3

This shows the preparation of (R)-1-[4-(3,4-Dichloro-phenoxy)-piperidin-1-yl]-3-methylamino-propan-2-ol



20 A solution of 4-(3,4-dichlorophenoxy)-1-[(2*R*)-oxiran-2-ylmethyl]piperidine (1g, 3.31mmol, prepared as described in the first part of preparation 2 and concentrated from DMF) and methylamine (2.56ml 40% in H₂O, 33.1mmol) in ethanol (15ml) was heated at 60°C in a sealed vessel for 16h. The solvent was evaporated at reduced pressure and the residue purified by flash column chromatography eluting with 8% 7M ammonia methanol in dichloromethane to give the title compound (875mg).

25

MS (APCI+ve) 333/335 (M+H)⁺


¹H NMR δ (CDCl₃) 2.38-2.27 (3H, m), 2.46 (3H, s), 2.48-2.42 (2H, m), 2.54 (1H, dd), 2.56-2.51 (2H, m), 2.65 (1H, dd), 2.71-2.65 (2H, m), 2.91-2.86 (1H, m), 3.86-3.80 (1H, m), 4.32-4.26 (1H, m), 6.75 (1H, dd), 6.99 (1H, d), 7.31 (1H, d).

30

23

Preparation 4

This shows the preparation of (R)-1-[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]-3-(methylamino)propan-2-ol




5 Prepared as described in Preparation 2 and 3 from 4-(2,4-dichloro-3-methylphenoxy)piperidine to give the title compound.

¹H NMR δ (CDCl₃) 1.58 - 2.00 (4H, m), 2.28 - 2.71 (10H, m), 2.46 (3H, s), 2.87 - 2.95 (1H, m), 3.49 (1H, s), 3.82 - 3.88 (1H, m), 4.33 - 4.39 (1H, m), 6.75 (1H, d), 7.19 (1H, d).

10

Example 1

N-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxamide



15 6-Oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxylic acid (Organic Process Research and Development 1997, 1, 370 - 378; 500 mg, 2.4 mmol) was dissolved in thionyl chloride (10 ml) and heated at reflux for 3 hours. The solvent was evaporated and the residue azeotroped with toluene (10 ml). The resultant pale yellow solid was dissolved in ethyl acetate (10 ml) and added dropwise to a solution of (2*R*)-1-amino-3-[4-(3,4-20 dichlorophenoxy)piperidin-1-yl]propan-2-ol (770 mg, 2.4 mmol) and triethylamine (1.68 ml, 12.0 mmol) in dichloromethane (25 ml). The mixture was stirred at room temperature for 18h and the solvents were evaporated. The residue was dissolved in methanol (20ml) and heated at reflux for 18 hours. The solvents were evaporated and purification by reverse phase HPLC (Novapak, 0.1% ammonium acetate / acetonitrile) afforded the title 25 compound as a colourless solid (520 mg, 43%).

The title compound has pKa 5.9 (measured using method B), and pKa 6.3 (calculated by ACD).

MS (APCI+ve) 508/510(M+H)⁺


24

¹H NMR δ (CD₃OD) 1.89 - 1.78 (2H, m), 2.10 - 1.99 (2H, m), 2.65 - 2.51 (4H, m), 2.99 - 2.87 (2H, m), 3.40 - 3.34 (1H, m), 3.48 (1H, dd), 4.04 - 3.96 (1H, m), 4.50 - 4.42 (1H, m), 6.84 (1H, d), 6.92 (1H, ddd), 7.14 (1H, dd), 7.41 (1H, dd), 7.75 (1H, d).

5

Example 2

N-(2*R*)-3-[4-(2,4-Dichloro-3-methylphenoxy)piperidin-1-yl]-2-hydroxypropyl)-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxamide.



6-Oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxylic acid (100 mg, 0.48 mmol) was dissolved in thionyl chloride (2 ml) and heated at reflux for 3 hours. The solvent was evaporated and the residue azeotroped with toluene (5 ml). The resultant pale yellow solid was dissolved in tetrahydrofuran (2 ml) and added dropwise to a solution of (2*R*)-1-amino-3-[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]propan-2-ol (161mg, 0.48mmol, Preparation 2) and triethylamine (337μl, 2.41mmol) in dichloromethane (5ml). The mixture was stirred at room temperature for 18h and the solvents were evaporated. The residue was dissolved in methanol (10ml) and heated at reflux for 3 hours. The solvents were evaporated and purification by reverse phase HPLC (Symmetry, 0.1% ammonium acetate / acetonitrile) afforded the title compound as a colourless solid (520 mg, 61%).


20 MS (APCI+ve) 522/524(M+H)⁺


¹H NMR δ (CD₃OD) 1.97 - 2.23 (4H, m), 2.48 (3H, s), 2.81 - 3.07 (4H, m), 3.12 - 3.24 (2H, m), 3.31 - 3.52 (2H, m), 4.08 - 4.18 (1H, m), 4.62 - 4.69 (1H, m), 6.89 (1H, d), 7.02 (1H, d), 7.31 (1H, d), 7.80 (1H, d).

25

Example 3

5-Bromo-*N*-(2*R*)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl)-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxamide.



Step 1: Ethyl 5-bromo-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxylate


To a solution of ethyl 6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxylate (Organic Process Research and Development 1997, 1, 370 – 378; 100 mg, 0.42 mmol) in

5 carbon tetrachloride was added N-bromosuccinimide (83mg, 0.46mmol). The mixture was heated at 80°C for 24 hours. Evaporation and the purification by flash column chromatography to give the subtitle compound as a colourless solid (100mg, 76%).

MS (ES -ve) 311/313 (M-H)⁺

¹H NMR δ (CDCl₃) 1.38 (3H, t), 4.39 (2H, q), 8.34 (1H, s)

10

Step 2: 5-Bromo-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxylic acid

Ethyl 5-bromo-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxylate (250mg, 0.79mmol) was suspended in 30% HCl and heated at reflux for 4 days. Cooling 15 and filtration gave the subtitle compound (210mg, 93%).

¹H NMR δ(DMSO-d₆) 8.40 (1H, s), 13.40 (1H, s), 13.70 (1H, s).

Step 3: 5-Bromo-N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxamide.


20 Made by the method of Example 1 using 5-bromo-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxylic acid (100mg, 0.35mmol), thionyl chloride (2ml), Preparation 1 (112mg, 0.35mmol) and triethylamine (244μl, 1.75mmol) to yield the title compound as a colourless solid (96mg, 46%).

MS (APCI-ve) 586 (M-H)⁺


25 ¹H NMR δ (CD₃OD) 1.99 - 2.13 (2H, m), 2.14 - 2.28 (2H, m), 2.97 - 3.28 (4H, m), 3.30 - 3.50 (4H, m), 4.13 - 4.22 (1H, m), 4.63 - 4.70 (1H, m), 6.98 (1H, dd), 7.22 (1H, d), 7.44 (1H, d), 7.88 (1H, s).

Example 4

N-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-2,3-dihydro-2-oxo-4-(trifluoromethyl)-5-thiazolecarboxamide



Step 1: 2,3-Dihydro-2-oxo-4-(trifluoromethyl)-5-thiazolecarboxamide



5

To a solution of ethyl 2,3-dihydro-2-oxo-4-(trifluoromethyl)-5-thiazolecarboxylic acid (Bionet Research, catalogue reference 4T-0262, 2.0 g, 8.3 mmoles) in tetrahydrofuran (20 ml) was added a solution of lithium hydroxide (0.696g, 16.6 mmoles) in water (20 ml). The mixture was stirred at 50°C for 72 hours, cooled to room temperature and filtered. The filtrate was washed with ethyl acetate (10 ml), acidified to pH 3 using dilute hydrochloric acid and extracted with ethyl acetate (2x 25 ml). The combined organic extractions were washed with water (2x 50 ml), saturated brine solution, dried (Na_2SO_4), filtered and concentrated *in vacuo* to give the subtitle compound as a colourless solid (1.583g, 90%).

10 MS (APCI-ve) 212 (M-H)⁻
 15 ¹³C NMR δ (CDCl_3) 171.3 (s), 161.1 (s), 129.8 (q, 39.8 Hz), 122.3 (q, 272.4 Hz),
 115.1 (q, 3.0 Hz).


Step 2:

20 *N*-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-2,3-dihydro-2-oxo-4-(trifluoromethyl)-5-thiazolecarboxamide was prepared as in Example 1 using 2,3-dihydro-2-oxo-4-(trifluoromethyl)-5-thiazolecarboxylic acid instead of 6-oxo-2-(trifluoromethyl)-1,6-dihydropyridine-3-carboxylic acid to afford the title compound as a cream foam (183 mg, 71%).

25 The title compound has a pKa 4.7 (measured using Method B).
 MS (APCI-ve) 512/514 (M-H)⁻
¹H NMR δ (CD_3OD) 2.06 - 1.94 (2H, m), 2.22 - 2.08 (2H, m), 3.00 - 2.86 (2H, ddd), 3.14 - 3.00 (2H, m), 3.30 - 3.18 (2H, m), 3.42 - 3.32 (2H, ddd), 4.11 - 4.03 (1H, m), 4.64 - 4.56 (1H, m), 6.94 (1H, dd), 7.18 (1H, d), 7.41 (1H, d).

Example 5

N-(2*S*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-*N*-methyl-2-oxo-4-(trifluoromethyl)-2,3-dihydro-1,3-thiazole-5-carboxamide



5

Prepared as Example 1 using (2*R*)-1-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-3-(methylamino)propan-2-ol (150mg, 0.45 mmol) and 2-oxo-4-(trifluoromethyl)-2,3-dihydro-1,3-thiazole-5-carboxylic acid (96mg, 0.45mmol) to yield the title compound as a colourless solid (85mg, 36%).


10 MS (APCI+ve) 528/530(M+H)⁺

¹H NMR δ (DMSO-d₆, 90°C) 1.79 - 1.62 (2H, m), 2.03 - 1.88 (2H, m), 2.62 - 2.45 (2H, m), 2.93 - 2.82 (4H, m), 3.00 (3H, s), 3.24 (1H, dd), 3.52 (1H, dd), 3.91 (1H, quintet), 4.45 (1H, septet), 6.96 (1H, dd), 7.20 (1H, d), 7.46 (1H, d).

15

Example 6

N-(2*S*)-3-[4-(2,4-Dichloro-3-methylphenoxy)piperidin-1-yl]-2-hydroxypropyl}-*N*-methyl-2-oxo-4-(trifluoromethyl)-2,3-dihydro-1,3-thiazole-5-carboxamide




Prepared as Example 1 using (2*R*)-1-[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]-3-(methylamino)propan-2-ol (156mg, 0.45 mmol) and 2-oxo-4-(trifluoromethyl)-2,3-dihydro-1,3-thiazole-5-carboxylic acid (96mg, 0.45mmol) to yield the title compound as a colourless solid (91mg, 39%).

20 MS (APCI+ve) 542/544(M+H)⁺


¹H NMR δ (DMSO-d₆, 90°C) 1.83 - 1.67 (2H, m), 2.01 - 1.87 (2H, m), 2.41 (3H, s), 2.61 - 2.50 (2H, m), 2.93 - 2.78 (4H, m), 2.99 (3H, s), 3.24 (1H, dd), 3.52 (1H, dd), 3.91 (1H, quintet), 4.47 (1H, septet), 7.05 (1H, d), 7.31 (1H, d).

Example 7

N-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-2-oxo-4-(pentafluoroethyl)-2,3-dihydro-1,3-thiazole-5-carboxamide



Step 1 2-Oxo-4-(pentafluoroethyl)-2,3-dihydro-1,3-thiazole-5-carboxylic acid



5 Ethyl 2-oxo-4-(pentafluoroethyl)-2,3-dihydro-1,3-thiazole-5-carboxylate
 (J.Het.Chem. 22 (1985) 1621-1630; 240mg, 0.82mmol) in tetrahydrofuran (6ml) was
 treated with lithium hydroxide (120mg) in water (5ml) and the mixture was heated at 50°C
 for 4 days. The mixture was filtered and the residue was washed with water. The filtrate
 10 was washed with ethyl acetate. The aqueous layer was acidified with dilute hydrochloric
 acid and then extracted with ethyl acetate (3x50ml). The organic extracts were washed
 with water and brine and then dried over sodium sulphate, filtered and evaporated to yield
 the subtitle compound as a solid (0.13g, 60%).

15 Step 2

Prepared as Example 1 using (2R)-1-amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol (158mg, 0.47 mmol) and 2-oxo-4-(pentafluoroethyl)-2,3-dihydro-1,3-thiazole-5-carboxylic acid (130mg, 0.49mmol) to yield the title compound as a colourless solid (74mg, 36%).

20 MS (APCI+ve) 564/566(M+H)⁺


¹H NMR δ(DMSO-d₆) 1.86 - 1.72 (2H, m), 2.08 - 1.96 (2H, m), 2.84 - 2.59 (4H, m); 3.10 - 2.90 (1H, m, obscured), 3.28 - 3.16 (3H, m), 3.85 (1H, quintet), 4.53 (1H, septet), 6.98 (1H, dd), 7.23 (1H, d), 7.47 (1H, d), 7.48 (1H, s).

25

Example 8

N-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-5-methyl-1*H*-1,2,3-triazole-4-carboxamide

29



Prepared as Example 1 using 5-methyl-1H-1,2,3-triazole-4-carboxylic acid (Berichte (1963) 96 802 – 812; 60 mg, 0.5 mmol) to yield the title compound as a colourless solid (63 mg, 31%).


5 The title compound has a pKa 7.5 (measured using Method B), and pKa 7.5 (calculated using ACD).

MS (APCI+ve) 428/430(M+H)⁺

10 ¹H NMR δ (DMSO-d₆) 1.73 - 1.60 (2H, m), 1.97 - 1.86 (2H, m), 2.41 - 2.28 (4H, m), 2.45 (3H, s), 2.79 - 2.67 (2H, m), 3.43 - 3.24 (2H, m), 3.78 (1H, quintet), 4.39 (1H, septet), 6.95 (1H, dd), 7.18 (1H, d), 7.44 (1H,d), 7.90 (1H, t),

Example 9

N-(2R)-3-[4-(2,4-Dichloro-3-methylphenoxy)piperidin-1-yl]-2-hydroxypropyl-5-methyl-1H-1,2,3-triazole-4-carboxamide



15

Prepared as Example 1 using (2R)-1-amino-3-[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]propan-2-ol (158mg, 0.47 mmol) and 5-methyl-1H-1,2,3-triazole-4-carboxylic acid to yield the title compound as a colourless solid (37mg, 18%).

The title compound has a pKa 7.5 (calculated using ACD).

20 MS (APCI+ve) 442/444(M+H)⁺


¹H NMR δ (DMSO-d₆, 90°C) 1.78 - 1.65 (2H, m), 1.97 - 1.86 (2H, m), 2.43 - 2.32 (4H, m), 2.41 (3H, s), 2.45 (3H, s), 2.79 - 2.67 (2H, m), 3.28 (1H, dt), 3.40 (1H, dt), 3.78 (1H, quintet), 4.43 (1H, septet), 7.03 (1H, d), 7.30 (1H, d), 7.89 (1H, t).

25

Example 10

5-Cyano-*N*-(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxamide

30



5-Cyano-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxylic acid

(Farmaco (1997) **52**(5) 331 – 337; 115 mg, 0.5 mmol) was dissolved in thionyl chloride (3 ml) and heated at reflux for 2 hours. The solvent was evaporated and the residue was 5 azeotroped with toluene (10 ml). The resultant solid was dissolved in tetrahydrofuran (5 ml) and added dropwise to a solution of (2R)-1-[4-(3,4-dichloro-phenoxy)-piperidin-1-yl]-3-methylamino-propan-2-ol (150 mg, 0.47 mmol) and triethylamine(0.3 ml, 2.1 mmol) in dichloromethane (5 ml). The mixture was stirred at room temperature for 18h and the solvents were evaporated. Purification by reverse phase HPLC (Novapack, 0.1% 10 ammonium acetate / acetonitrile) and normal phase chromatography (NH3/methanol/dichloromethane) afforded the title compound as a colourless solid (123 mg, 49%).


The title compound has a pKa 3.4 (calculated using ACD).

MS (APCI+ve) 533/535(M+H)⁺

15 ¹H NMR δ (CD₃OD) 2.13 – 1.99 (2H, m), 2.28 - 2.13 (2H, m), 3.10 (2H, dt), 3.34-3.14(2H, m), 3.50-3.36(4H, m), 4.21-4.12 (1H, m), 4.71-4.63 (1H, m), 6.96 (1H, dd), 7.21 (1H, d), 7.42 (1H, d), 7.85 (1H, s).

Example 11

20 5-Cyano-N-[(2R)-3-[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]-2-hydroxypropyl]-6-oxo-2-(trifluoromethyl)-1,6-dihdropyridine-3-carboxamide



25 Prepared as Example 1 using (2R)-1-amino-3-[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]propan-2-ol to yield the title compound as a colourless solid (121mg, 49%).

The title compound has a pKa 3.4 (calculated using ACD).


MS (APCI+ve) 547/549(M+H)⁺

¹H NMR δ (DMSO-d₆+ND₄OD) 1.72 - 1.61 (2H, m), 1.93 - 1.84 (2H, m), 2.37 - 2.24 (4H, m), 2.40 (3H, s), 2.72 - 2.63 (2H, m), 3.07 (1H, dd), 3.23 (1H, dd), 3.71 (1H, quintet), 4.48 (1H, septet), 7.10 (1H, d), 7.34 (1H, d), 7.66 (1H, s).

5

Example 12

5-Cyano-N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-6-oxo-2-phenyl-1,6-dihdropyridine-3-carboxamide



10 5-Cyano-6-oxo-2-phenyl-1,6-dihdropyridine-3-carboxylic acid (European Journal of Medicinal Chemistry, 24(5), 517 - 519, (1989); 112 mg, 0.47 mmol) was dissolved in thionyl chloride (4 mL) and heated under reflux for 2 h. The solvent was removed *in vacuo* and the residue azeotroped with toluene (10 mL). The resultant pale yellow solid was dissolved in tetrahydrofuran (4 mL) and added dropwise to a solution of (2R)-1-amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol (150 mg, 0.47 mmol) and 15 triethylamine (0.7 mL, 5.0 mmol) in dichloromethane (2 mL). The mixture was stirred at room temperature overnight and the volatiles removed *in vacuo*. The residue was dissolved in acetonitrile (6 mL) and purification by reverse phase HPLC (Novapak, 0.1% ammonium acetate / acetonitrile) afforded the title compound as a white solid, which on dissolving in dichloromethane, gave a dry yellow powder (25 mg, 10 %).

20


The title compound has a pKa 6.3 (calculated using ACD).

MS (APCI+ve) 541/543(M+H)⁺

¹H NMR δ(DMSO-d₆) 1.54 - 1.64 (2H, m), 1.84 - 1.95 (2H, m), 2.12 - 2.35 (4H, m), 2.62 - 2.73 (2H, m), 2.92 - 3.00 (1H, m), 3.11 - 3.20 (1H, m), 3.53 - 3.61 (1H, m), 4.38 - 4.49 (1H, m), 4.56 - 4.76 (1H, br s), 6.98 (1H, dd), 7.25 (1H, d), 7.42 - 7.53 (6H, m), 8.11 - 8.25 (1H, t), 8.23 (1H, s).

Example 13

5-Cyano-N-[(2R)-3-[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]-2-hydroxypropyl]-6-oxo-2-phenyl-1,6-dihdropyridine-3-carboxamide



5-Cyano-6-oxo-2-phenyl-1,6-dihdropyridine-3-carboxylic acid (European Journal of Medicinal Chemistry, 24 (5), 517 – 519, 1989; 112 mg, 0.47 mmol) was dissolved in thionyl chloride (4 mL) and heated under reflux for 2 h. The solvent was removed *in vacuo* and the residue azeotroped with toluene (10 mL). The resultant pale yellow solid was dissolved in tetrahydrofuran (4 mL) and added dropwise to a solution of (2*R*)-1-amino-3-[4-(2,4-dichloro-3-methylphenoxy)piperidin-1-yl]propan-2-ol (150 mg, 0.47 mmol) and triethylamine (0.7 mL, 5.0 mmol) in dichloromethane (2 mL). The mixture was stirred at room temperature overnight and the volatiles removed *in vacuo*. The residue was dissolved in acetonitrile (6 mL) and purification by reverse phase HPLC (Novapak, 0.1% ammonium acetate / acetonitrile) afforded the title compound as a dry yellow powder (11 mg, 4 %).

The title compound has a pKa 6.3 (calculated using ACD).


MS (APCI+ve) 555/557(M+H)⁺

15 ¹H NMR δ(CDCl₃) 1.92 - 2.01 (2H, m), 2.06 - 2.21 (3H, m), 2.47 (3H, s), 2.50 - 2.56 (2H, m), 2.76 - 2.83 (1H, m), 2.87 (1H, td), 2.96 - 3.05 (2H, m), 3.06 - 3.15 (1H, m), 3.35 - 3.43 (1H, m), 4.50 - 4.55 (1H, m), 6.33 - 6.39 (1H, m), 6.74 (1H, d), 7.22 (1H, d), 7.47 - 7.51 (5H, m), 7.51 - 7.57 (1H, m), 8.22 (1H, s)

20


Example 14

N-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-3-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamide



Step 1: 3-Methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid

33



The subtitle compound was synthesized according to the procedure described in *Pharmazie* **48** (1993), H. 11 861 - 862.

5 **Step 2:** *N*-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-3-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamide

3-Methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid (*Pharmazie* **48** (1993), H. 11, 861 – 862; 173 mg, 1.02 mmol) was dissolved in thionyl chloride (8 mL) and heated under reflux for 2 h. The solvent was removed *in vacuo* and the residue azeotroped with toluene (10 mL). The resultant pale yellow solid was dissolved in tetrahydrofuran (4 mL) and added dropwise to a solution of (2*R*)-1-amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol (325 mg, 1.02 mmol) and triethylamine (1.56 mL, 11.1 mmol) in dichloromethane (4.5 mL). The mixture was stirred at room temperature overnight and the volatiles removed *in vacuo*. The residue was dissolved in acetonitrile (6 mL) and purification by reverse phase HPLC (Novapack, 0.1% ammonium acetate / acetonitrile) followed by trituration with dichloromethane afforded the title compound as a dry yellow powder (8 mg, 2 %).

The title compound has a pKa 6.9 (calculated using ACD).


MS (APCI+ve) 471/473(M+H)⁺

20 ¹H NMR δ (CD₃OD) 1.26 - 1.36 (2H, m), 1.78 - 1.85 (2H, m), 1.99 - 2.05 (2H, m), 2.55 - 2.60 (2H, m), 2.83 - 2.95 (2H, m), 3.11 - 3.14 (1H, m), 3.32 (3H, s), 3.49 - 3.52 (1H, m), 3.89 - 4.01 (1H, m), 4.41 - 4.47 (1H, m), 5.58 (1H, s), 5.78 (1H, d), 6.88 - 6.91 (1H, m), 7.11 (1H, d) 7.38 (1H, d).


25

Example 15

N-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-2,6-dioxo-3-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyrimidine-4-carboxamide



Step 1: 2,6-Dioxo-3-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid



The subtitle compound was synthesized according to the procedure described in
 5 *Pharmazie* **48** (1993), H. 11 861 - 862.

Step 2: *N*-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-2,6-dioxo-3-(2,2,2-trifluoroethyl)-1,2,3,6-tetrahydropyrimidine-4-carboxamide

To a solution of (2*R*)-1-amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-
 10 ol (134 mg, 0.42 mmol) in dry dimethylformamide (3 mL), was added *N,N*-
 diisopropylethylamine (0.14 mL, 0.84 mmol), 2,6-dioxo-3-(2,2,2-trifluoroethyl)-1,2,3,6-
 tetrahydropyrimidine-4-carboxylic acid (100 mg, 0.42 mmol) and HATU (178 mg, 0.462
 mmol). The reaction mixture was stirred at 0°C under an atmosphere of nitrogen for 20
 min, then quenched with saturated sodium bicarbonate solution (10 mL), and allowed to
 15 stand overnight. The mixture was extracted with ethyl acetate (3 x 10 mL), the combined
 organics washed with brine (2 x 10 mL), dried over anhydrous magnesium sulfate, and the
 volatiles removed *in vacuo* to give an oil (205 mg). Purification by reverse phase HPLC
 (Novapak, 0.1% ammonium acetate / acetonitrile) afforded the title compound (28 mg, 12
 %) the title compound as a dry yellow powder (8 mg, 2 %).

20 The title compound has a pKa 5.9 (calculated using ACD).


MS (APCI+ve) 539/541(M+H)⁺

¹H NMR (CD₃OD) δ 1.83 - 1.68 (2H, m), 2.03 - 1.90 (2H, m), 2.29- 2.24(1H, m),
 2.45 - 2.34 (1H, m), 2.69 - 2.51 (4H, m), 2.97 - 2.84 (2H, m), 3.03 (1H, quintet), 3.26 -
 3.23 (1H, m), 3.34 - 3.32 (1H, m), 3.37 - 3.35 (1H, m), 3.90 (1H, quintet), 4.40 (1H,
 25 quintet), 5.39 (1H, s), 5.93 (1H, s), 6.82 (1H, dd), 7.04 (1H, d) 7.30 (1H, d).

Example 16

35

5-Cyano-2-cyclopropyl-N-[(2R)-3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-2-hydroxypropyl]-1,6-dihydro-6-oxo-3-pyridinecarboxamide



A stirred solution of 5-cyano-2-cyclopropyl-6-oxo-1,6-dihdropyridine-3-carboxylic acid (0.080 g) [J. Med. Chem. (2002) 45 1887] in thionyl chloride (2.5 mL) was heated at reflux for 2 h. Thionyl chloride was removed from the cooled solution *in vacuo*. The residue was dissolved in tetrahydrofuran (4 mL) and this solution was added dropwise at room temperature to a solution of (2R)-1-amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol (0.125 g) and triethylamine (0.7 mL) in dichloromethane (2 mL) before stirring overnight. The reaction mixture was concentrated *in vacuo* and redissolved in 9 : 1 acetonitrile/water (4 mL) before subjecting to RPHPLC (gradient 0.1% ammonium acetate/acetonitrile 95% to 50%) to yield a white solid (0.022 g).

The title compound has a pKa 6.0 (calculated using ACD).


MS (ES+ve) 505/507 [M+H]⁺

¹H NMR δ (DMSO-d₆) 1.02 - 1.08 (2H, m), 1.11 - 1.17 (2H, m), 1.57 - 1.68 (2H, m), 1.89 - 1.97 (2H, m), 2.30 - 2.43 (4H, m), 2.53 - 2.61 (1H, m), 2.72 - 2.85 (2H, m), 3.05 - 3.14 (1H, m), 3.74 - 3.81 (1H, m), 4.42 - 4.49 (1H, m), 6.98 (1H, dd), 7.26 (1H, d), 7.50 (1H, d), 8.10 (1H, s), 8.32 (1H, t); resonance at ~3.3 (1H, m) obscured by HDO.

20

Example 17

5-Cyano-2-cyclopropyl-N-[(2R)-3-[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]-2-hydroxypropyl]-1,6-dihydro-6-oxo-3-pyridinecarboxamide




MS (ES+ve) 519/521 [M+H]⁺

¹H NMR δ (DMSO-d₆) 1.00 - 1.07 (2H, m), 1.10 - 1.17 (2H, m), 1.62 - 1.73 (2H, m), 1.86 - 1.93 (2H, m), 2.30 - 2.39 (4H, m), 2.40 (3H, s), 2.52 - 2.61 (1H, m), 2.66 - 2.78 (2H, m), 3.04 - 3.13 (1H, m), 3.73 - 3.80 (1H, m), 4.46 - 4.54 (1H, m), 7.10 (1H, d), 7.35 (1H, d), 8.07 (1H, s), 8.29 (1H, t); resonance at ~3.3 (1H, m) obscured by HDO.

30

Example 18

N-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-6-[(methylsulfonyl)amino]-4-(trifluoromethyl)nicotinamide



5 Step 1: 6-Chloro-*N*-{(2*R*)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-4-(trifluoromethyl)nicotinamide

A solution of 4-trifluoromethyl-6-chloronicotinoyl chloride (0.585 g) in tetrahydrofuran (3 mL) was added dropwise at room temperature to a stirred solution of (2*R*)-1-amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol (0.735 g) and triethylamine (0.7 mL) in dichloromethane (2 mL) before stirring overnight.

10 The reaction mixture was concentrated *in vacuo* and subjected to flash column chromatography (eluent 96 : 4 dichloromethane/7 N ammonia in methanol) to yield a yellow oil (1.02 g). A small amount (0.1 g) was redissolved in 9 : 1 acetonitrile/water (4 mL) and subjected to RPHPLC (gradient 0.1% ammonium acetate/acetonitrile 95% to 5%) to yield a white solid (0.025 g).

15 MS (ES+ve) 526/528 [M+H]⁺

¹H NMR δ (CD₃OD) 1.66 - 1.80 (2H, m), 1.87 - 2.00 (2H, m), 2.42 - 2.57 (4H, m), 2.76 - 2.90 (2H, m), 3.27 (1H, dd), 3.44 (1H, dd), 3.86 - 3.95 (1H, m), 4.30 - 4.41 (1H, m), 6.80 (1H, dd), 7.02 (1H, d), 7.29 (1H, d), 7.78 (1H, s), 8.56 (1H, s).

20 Step 2: *N*-{(2*R*)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-6-[(methylsulfonyl)amino]-4-(trifluoromethyl)nicotinamide

A stirred solution of 6-chloro-*N*-{(2*R*)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-4-(trifluoromethyl)nicotinamide (0.28 g), methanesulfonamide (0.12 g) and potassium carbonate (0.148 g) in *N*-methyl-2-pyrrolidinone was heated under microwave irradiation (100 W) at 100°C for 15 min. The reaction mixture was concentrated *in vacuo* and redissolved in 4 : 1 : 1 acetonitrile/ water/acetic acid (6 mL) and subjected to RPHPLC (gradient 0.1% ammonium acetate/acetonitrile 95% to 5%) to yield a white solid (0.025 g).

The title compound has a pKa 5.3 (measured using Method B).


30 MS (ES+ve) 585/587 [M+H]⁺

¹H NMR δ (CD₃OD) 1.86 - 2.02 (2H, m), 2.06 - 2.20 (2H, m), 2.74 - 2.98 (4H, m),


3.07 - 3.22 (2H, m), 3.24 (3H, s), 3.36 - 3.56 (2H, m), 4.05 - 4.16 (1H, m), 4.52 - 4.62 (1H, m), 6.95 (1H, dd), 7.12 (1H, s), 7.18 (1H, d), 7.42 (1H, d), 8.44 (1H, s)

Example 19

5 N- $\{(2R)$ -3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-5-[(2,2,2-trifluoroethyl)thio]-1*H*-1,2,3-triazole-4-carboxamide



Step 1: Ethyl 1-(4-methoxybenzyl)-5-[(2,2,2-trifluoroethyl)thio]-1*H*-1,2,3-triazole-4-carboxylate




10 Sodium hydride (18mg, 0.73mmol) was added to a solution of 3,3,3-trifluoroethanol (60 μ l, 0.67mmol) in dry DMF (1.5ml). After stirring at room temperature for 30min a solution of ethyl 5-chloro-1*H*-1,2,3-triazole-4-carboxylate (0.20g, 0.67mmol, J.Chem. Soc. Perkin I, (1982) 627) in dry DMF (1ml) was added. The mixture was heated at 80°C for 18h then cooled and partitioned between diethyl ether and water (50ml/50ml). The aqueous layer was reextracted with diethyl ether (2 x 50ml) and the combined extracts dried over anhydrous sodium sulfate. Concentration in vacuo and chromatography on silica (EtOAc:isohexane/0-50% gradient) gave the subtitle compound (127mg)

15 MS (ES+ve) 376 [M+H]⁺

20 ¹H NMR δ (CDCl₃) 1.44 (3H, t), 3.66 (2H, q), 3.78 (3H, s), 4.46 (2H, q), 5.62 (2H, s), 6.89-6.83 (2H, m), 7.29-7.24 (2H, m).

Step 2: Ethyl 5-[(2,2,2-trifluoroethyl)thio]-1*H*-1,2,3-triazole-4-carboxylate



25 Ethyl 1-(4-methoxybenzyl)-5-[(2,2,2-trifluoroethyl)thio]-1*H*-1,2,3-triazole-4-carboxylate (0.127g, 0.34mmol) was dissolved in trifluoroacetic acid (2ml) and heated at


65°C for 4h. The trifluoroacetic acid was evaporated in vacuo and the residue azeotroped with toluene (3 x 10ml) then dried under vacuum to afford the subtitle compound (86mg).

MS (ES-ve) 234 [M-HF]⁻

¹H NMR δ(CDCl₃) 1.44 (3H, t), 3.89 (2H, q), 4.46 (2H, q).

5

Step 3: 5-[(2,2,2-Trifluoroethyl)thio]-1*H*-1,2,3-triazole-4-carboxylic acid



Ethyl 5-[(2,2,2-trifluoroethyl)thio]-1*H*-1,2,3-triazole-4-carboxylate (86mg, 0.34mmol) was suspended in 1N aqueous sodium hydroxide solution and heated at 70°C for 3h. The aqueous was filtered and then acidified with concentrated hydrochloric acid. Concentration in vacuo afforded a colourless solid which was washed with ice cold water to afford the subtitle compound (80mg)

MS (ES-ve) 226 [M-H]⁻

¹H NMR δ(DMSO- d₆) 4.09-4.22 (2H, m), 13.51 (1H, s), 15.75 (1H, s).

15

Step 4: *N*-{(2*R*)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}-5-[(2,2,2-trifluoroethyl)thio]-1*H*-1,2,3-triazole-4-carboxamide

5-[(2,2,2-Trifluoroethyl)thio]-1*H*-1,2,3-triazole-4-carboxylic acid (80mg, 0.34mmol) was dissolved in dichloromethane (2ml) and treated with oxalyl chloride (60μl, 0.68mmol) and DMF (1 drop). The solution was stirred at room temperature for 1h then concentrated in vacuo and azeotroped with anhydrous toluene (5ml). The residue was redissolved in dry tetrahydrofuran and added dropwise to a stirred solution of (2*R*)-1-amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol (0.108g, 0.34mmol) and triethylamine (142μl, 1mmol) in dichloromethane. The mixture was stirred for 1h, the solvent was evaporated in vacuo and the product purified by RPHPLC (gradient 0.1% ammonium acetate/acetonitrile 50% to 5%) to afford the title compound as a colourless solid (58mg).

The title compound has a pKa 4.6 (calculated using ACD).


MS (ES+ve) 528/530 [M+H]⁺

¹H NMR δ (CD₃OD) 1.92 - 1.84 (2H, m), 2.09 - 1.98 (2H, m), 2.92 - 2.72 (4H, m), 3.13 - 3.04 (2H, m), 3.42 - 3.32 (2H, m), 3.82 (2H, q), 4.03 - 3.97 (1H, m), 4.50 - 4.43 (1H, m), 6.83 (1H, dd), 7.07 (1H, d), 7.30 (1H, d).

5

Example 20

4-[({(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl}amino)-carbonyl]-1-naphthoic acid



To a solution of naphthalene-1,4-dicarboxylic acid (100mg, 0.48mmol), (2R)-1-amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol (147mg, 0.46mmol) and triethylamine (193 µl, 1.38mmol) in N-methyl-2-pyrrolidinone (20ml) was added PyBrOP (258mg, 0.56mmol). The reaction mixture was stirred for 16 hours and the solvent evaporated. The residue was purified by reverse phase HPLC (Symmetry, 0.1% ammonium acetate / acetonitrile) afforded the title compound as a colourless solid (50 mg, 15 20%).

MS (APCI+ve) 517/519 (M+H)⁺
¹H NMR δ(CD₃OD) 2.02 - 2.30 (4H, m), 3.09 - 3.20 (2H, m), 3.22 - 3.30 (2H, m), 3.38 - 3.47 (2H, m), 3.51 - 3.67 (2H, m), 4.26 - 4.35 (1H, m), 4.66 - 4.73 (1H, m), 6.99 (1H, dd), 7.23 (1H, d), 7.45 (1H, d), 7.53 - 7.59 (2H, m), 7.64 (1H, d), 7.69 (1H, d), 8.23 - 8.26 (1H, m), 8.57 - 8.60 (1H, m).

Example 21

Pharmacological Analysis: Calcium flux [Ca²⁺]_i assay

Human eosinophils

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended (5x10⁶ ml⁻¹) and loaded with 5µM FLUO-3/AM + Pluronic F127 2.2µl/ml (Molecular Probes) in low potassium solution (LKS; NaCl 118mM, MgSO₄ 0.8mM, glucose 5.5mM, Na₂CO₃ 8.5mM, KCl 5mM, HEPES 20mM, CaCl₂ 1.8mM, BSA 30 0.1%, pH 7.4) for one hour at room temperature. After loading, cells were centrifuged at 200g for 5min and resuspended in LKS at 2.5x10⁶ ml⁻¹. The cells were then transferred to

96 well FLIPr plates (Poly-D-Lysine plates from Becton Dickinson pre-incubated with 5 μ M fibronectin for twoh) at 25 μ l/well. The plate was centrifuged at 200g for 5min and the cells were washed twice with LKS (200 μ l; room temperature).

5 A compound of the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A₅₀ concentration of eotaxin and the transient increase in fluo-3 fluorescence ($\lambda_{Ex} = 490$ nm and $\lambda_{Em} = 520$ nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

10 Compounds of the Examples were found to be antagonists if the increase in fluorescence induced by eotaxin (a selective CCR3 agonist) was inhibited in a concentration dependent manner. The concentration of antagonist required to inhibit the fluorescence by 50% can be used to determine the IC₅₀ for the antagonist at the CCR3 receptor.

15

Example 22

Human eosinophil chemotaxis

20 Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended at 10x10⁶ ml⁻¹ in RPMI containing 200 IU/ml penicillin, 200 μ g/ml streptomycin sulfate and supplemented with 10% HIFCS, at room temperature.

25 Eosinophils (700 μ l) were pre-incubated for 15 mins at 37° C with 7 μ l of either vehicle or compound (100x required final concentration in 10% DMSO). The chemotaxis plate (ChemoTx, 3 μ m pore, Neuroprobe) was loaded by adding 28 μ l of a concentration of eotaxin 0.1 to 100nM (a selective CCR3 agonist over this concentration range) containing a concentration of a compound according to the Examples or solvent to the lower wells of the chemotaxis plate. The filter was then placed over the wells and 25 μ l of eosinophil suspension were added to the top of the filter. The plate was incubated for 1 hr at 37° C in a humidified incubator with a 95% air/5% CO₂ atmosphere to allow chemotaxis.

30 The medium, containing cells that had not migrated, was carefully aspirated from above the filter and discarded. The filter was washed once with phosphate buffered saline (PBS) containing 5 mM EDTA to remove any adherent cells. Cells that had migrated through the filter were pelleted by centrifugation (300xg for 5 mins at room temperature) and the filter removed and the supernatant transferred to each well of a 96-well plate

(Costar). The pelleted cells were lysed by the addition of 28 μ l of PBS containing 0.5% Triton x100 followed by two cycles of freeze/thawing. The cell lysate was then added to the supernatant. The number of eosinophils migrating was quantified according to the method of Strath et al., *J. Immunol. Methods*, 1985, 83, 209 by measuring eosinophil peroxidase activity in the supernatant.

Compounds of the Examples were found to be antagonists of eotaxin mediated human eosinophil chemotaxis if the concentration response to eotaxin was shifted to the right of the control curve. Measuring the concentration of eotaxin required to give 50% chemotaxis in the presence or absence of compounds enables the apparent affinity of the compounds at CCR3 to be calculated, or the assay can be used to determine activity of compounds at a set concentration of compound against a predefined concentration of eotaxin.

Example 23

15 Guinea-pig isolated trachea

(See for example, Harrison, R.W.S., Carswell, H. & Young, J.M. (1984) European J. Pharmacol., 106, 405-409.)

Male albino Dunkin-Hartley guinea-pigs (250g) were killed by cervical dislocation and the whole trachea removed. After clearing the adherent connective tissue, the trachea was cut into six ring segments each three cartilage bands wide and then suspended in 20ml organ baths containing Krebs-Henseleit solution of the following composition (mM): NaCl 117.6, NaH₂PO₄ 0.9, NaHCO₃ 25.0, MgSO₄ 1.2, KCl 5.4, CaCl₂ 2.6 and glucose 11.1. The buffer was maintained at 37°C and gassed with 5% CO₂ in oxygen. Indomethacin (2.8 μ M) was added to the Krebs solution to prevent development of smooth muscle tone due to the synthesis of cyclo-oxygenase products. The tracheal rings were suspended between two parallel tungsten wire hooks, one attached to an Ormed beam isometric force transducer and the other to a stationary support in the organ bath. Changes in isometric force were recorded on 2-channel Sekonic flat bed chart recorders.

Experimental protocols

At the beginning of each experiment a force of 1g was applied to the tissues and this was reinstated over a 60 minute equilibration period until a steady resting tone was achieved. Subsequently, a cumulative histamine concentration effect (E/[A]) curve was constructed at 0.5 log₁₀ unit increments, in each tissue. The tissues were then washed and

approximately 30 minutes later, test compound or vehicle (20% DMSO) was added. Following an incubation period of 60 minutes a second E/[A] curve was performed to histamine.

Contraction responses were recorded as a percentage of the first curve maximum.

5 Data analysis

Experimental E/[A] curve data were analysed for the purposes of estimating the potencies ($p[A_{50}]$ values) of histamine in the absence and presence of the test compound. Affinity (pA_2) values of test compounds were subsequently calculated using the following equation:

10 $\log(r-1) = \log[B] + pA_2$

where $r = [A]_{50}$ in presence of test compound/[A]₅₀ in absence of antagonist and [B] is the concentration of test compound. Compounds of the Examples were found to be H1 antagonists.

15 Example 24


Histamine H1 receptor binding activity of compounds of the invention was assessed by competition displacement of 1nM [³H]-pyrilamine (Amersham, Bucks, Product code TRK 608, specific activity 30Ci/mmol) to 2 μ g membranes prepared from recombinant CHO-K1 cells expressing the human H1 receptor (Euroscreen SA, Brussels, Belgium, product code ES-390-M) in assay buffer (50mM Tris pH 7.4 containing 2mM MgCl₂, 250mM sucrose and 100mM NaCl) for 1 hour at room temperature.

The following compounds of the invention gave inhibition of [³H] pyrilamine binding:

Example	H1 pKi
5	6.9
8	7.8
10	6.9
14	6.9
16	7.6

CLAIMS

1. A compound of formula (I):



5 wherein:

R¹ is phenyl optionally substituted by halogen, cyano, C₁₋₄ alkyl or C₁₋₄ haloalkyl;

R² is hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl; and,

R³ is a group having an NH or OH that has a calculated or measured pKa of 1.0 to 8.0;

10 or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

2. Processes for preparing the compounds as claimed in claim 1.

3. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, or solvate thereof, or a solvate of a salt thereof, as claimed in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier therefor.

4. A compound of the formula (I), or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, as claimed in claim 1, for use in therapy.


5. A compound of formula (I), or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, as claimed in claim 1, in the manufacture of a medicament for use in therapy.

25 6. A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, as claimed in claim 1.

30

ABSTRACTCHEMICAL COMPOUNDS

Compounds of formula (I):



5

are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma).